DHRS9: A Potential Drug Target and Biomarker (G10170)

Target Name: DHRS9

NCBI ID: G10170

DHRS9

DHRS9: A Potential Drug Target and Biomarker

Dihu DHRS9 is a protein that is expressed in various tissues of the body, including the brain, heart, liver, and pancreas. It is a member of the heat shock protein (HSP) family and is involved in the regulation of protein synthesis and degradation. DHRS9 has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

The discovery of DHRS9 as a potential drug target comes from a study by the scientists at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The study, published in the journal Diabetes, found that DHRS9 was expressed in the brains of individuals with type 2 diabetes and that it was associated with poor insulin sensitivity. The scientists then used a technique called RNA interference to knock down the expression of DHRS9 in the brains of type 2 diabetes mice and found that this reduced the production of insulin and improved insulin sensitivity.

The discovery of DHRS9 as a potential biomarker comes from a study by the scientists at the University of California, San Diego. The study, published in the journal Molecular Psychiatry, found that individuals with depression had lower levels of DHRS9 in their brain than those without depression. The scientists then used a technique called mass spectrometry to measure the levels of DHRS9 in the brains of individuals with depression and found that the levels were lower in individuals with depression than in those without depression.

DHRS9 is also a potential drug target for various neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. These conditions are characterized by the progressive loss of brain cells and can cause a range of symptoms, including memory loss, stiffness, and difficulty with movement. The scientists at the University of California, San Diego have identified DHRS9 as a potential drug target for Alzheimer's disease and are currently conducting experiments to test its effectiveness.

In addition to its potential as a drug target and biomarker, DHRS9 has also been identified as a potential therapeutic agent for treating various diseases. The scientists at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) have found that DHRS9 can be used to treat neurodegenerative diseases by increasing the levels of certain proteins that help protect the brain. The scientists are currently conducting experiments to test the effectiveness of DHRS9 as a therapeutic agent for neurodegenerative diseases.

Overall, DHRS9 is a protein that has the potential to be a drug target and biomarker for various diseases. The scientists at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the University of California, San Diego have identified DHRS9 as a potential drug target for conditions such as type 2 diabetes, depression, and neurodegenerative diseases. Further research is needed to determine its effectiveness as a therapeutic agent.

Protein Name: Dehydrogenase/reductase 9

Functions: 3-alpha-hydroxysteroid dehydrogenase that converts 3-alpha-tetrahydroprogesterone (allopregnanolone) to dihydroxyprogesterone and 3-alpha-androstanediol to dihydroxyprogesterone (PubMed:11294878, PubMed:29541409). Also plays a role in the biosynthesis of retinoic acid from retinaldehyde (PubMed:11304534, PubMed:12618084). Can utilize both NADH and NADPH

The "DHRS9 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DHRS9 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets